Management of Multiple Myeloma in the Middle East: Unmet Needs, Challenges and Perspective

[1]  He Huang,et al.  Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019 , 2021, BMC Cancer.

[2]  A. Taher,et al.  Changing Management of Hematological Malignancies With COVID-19: Statement and Recommendations of the Lebanese Society of Hematology and Blood Transfusion , 2021, Frontiers in Oncology.

[3]  H. Goldschmidt,et al.  Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. , 2021, The Lancet. Oncology.

[4]  F. Zhou,et al.  Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects , 2021, Frontiers in Medicine.

[5]  F. Farzadfar,et al.  A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017 , 2021, Experimental Hematology & Oncology.

[6]  H. Goldschmidt,et al.  Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  H. Goldschmidt,et al.  Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up , 2021, HemaSphere.

[8]  E. Wood,et al.  The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR). , 2021, Clinical lymphoma, myeloma & leukemia.

[9]  M. Dimopoulos,et al.  A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. , 2020, Blood advances.

[10]  G. Morgan,et al.  Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Martinelli,et al.  How I manage frontline transplant-ineligible multiple myeloma , 2020, Hematology reports.

[12]  F. Nasr,et al.  Lebanese experience in treating multiple myeloma: A multicenter retrospective study. , 2020 .

[13]  E. Raidullah,et al.  First Review of Multiple Myeloma Patients in Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates , 2019, Blood.

[14]  A. Alaskar,et al.  Multiple myeloma in Saudi Arabia: Consensus of the Saudi lymphoma/myeloma group , 2019, Journal of Applied Hematology.

[15]  M. Mohty,et al.  Current status of autologous stem cell transplantation for multiple myeloma , 2019, Blood Cancer Journal.

[16]  L. Rybicki,et al.  Progression with clinical features is associated with worse subsequent survival in multiple myeloma , 2019, American journal of hematology.

[17]  N. Puig,et al.  INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma , 2019, Future oncology.

[18]  F. Davies,et al.  Toward personalized treatment in multiple myeloma based on molecular characteristics. , 2019, Blood.

[19]  D. Dingli,et al.  Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse , 2018, Leukemia.

[20]  G. Chahine,et al.  Survival of Multiple Myeloma in the Lebanese Population between January 2005 and December 2017: MM‐184 , 2018, Clinical Lymphoma Myeloma and Leukemia.

[21]  L. Trippa,et al.  A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma , 2018, British journal of haematology.

[22]  C. Fitzmaurice,et al.  Global burden of multiple myeloma: A systematic analysis for the Global Burden of Disease study 2016. , 2018 .

[23]  M. Naghavi,et al.  Global Burden of Multiple Myeloma , 2018, JAMA oncology.

[24]  S. Tuchman,et al.  Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies , 2018, Clinical lymphoma, myeloma & leukemia.

[25]  J. H. Lee,et al.  Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop , 2018, Leukemia & lymphoma.

[26]  A. Bazarbachi,et al.  Trends in hematopoietic stem cell transplant activity in Lebanon. , 2017, Hematology/oncology and stem cell therapy.

[27]  Jean-Michel Nguyen,et al.  Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Rajkumar,et al.  Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. , 2016, Blood.

[29]  B. Barlogie,et al.  Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. , 2016, Blood.

[30]  M. Dimopoulos,et al.  Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  K. Anderson,et al.  Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. , 2015, Blood.

[32]  S. Jagannath,et al.  Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. , 2014, Clinical lymphoma, myeloma & leukemia.

[33]  H. Goldschmidt,et al.  European perspective on multiple myeloma treatment strategies in 2014. , 2014, The oncologist.

[34]  Michele Cavo,et al.  International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Yagüe,et al.  Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution , 2013, Haematologica.

[36]  G. Morgan,et al.  Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Terol,et al.  High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. , 2012, Blood.

[38]  J. Reeves,et al.  Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients , 2010 .

[39]  R. Fonseca,et al.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. , 2010, The Lancet. Oncology.

[40]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[41]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.